



**pan-Canadian Oncology Drug Review
Patient Advocacy Group Feedback on a pCODR
Expert Review Committee Initial
Recommendation**

**Olaparib (Lynparza) for Ovarian Cancer -
Resubmission**

September 20, 2017

1 Feedback on pERC Initial Recommendation

Name of the drug indication(s): Olaparib (Ovarian Cancer)

Name of registered patient group: Ovarian Cancer Canada

**pCODR may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by pCODR.*

1.1 Comments on the Initial Recommendation

a) Please indicate if the patient group agrees or disagrees with the initial recommendation:

agrees agrees in part disagree

Please explain why the patient group agrees, agrees in part or disagrees with the initial recommendation.

Ovarian Cancer Canada agrees with the initial recommendation as it is very important that women with BRCA mutated ovarian cancer have access to more treatment options.

b) Notwithstanding the feedback provided in part a) above, please indicate if the patient group would support this initial recommendation proceeding to final pERC recommendation (“early conversion”), which would occur two (2) Business Days after the end of the feedback deadline date.

Support conversion to final recommendation. Do not support conversion to final recommendation.
 Recommendation does not require reconsideration by pERC. Recommendation should be reconsidered by pERC.

c) Please provide feedback on the initial recommendation. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity

1.2 Comments Related to Patient Group Input

Please provide feedback on any issues not adequately addressed in the initial recommendation based on patient group input provided at the outset of the review on outcomes or issues important to patients that were identified in the submitted patient input. Please note that new evidence will be not considered during this part of the

review process, however, it may be eligible for a Resubmission. If you are unclear as to whether the information you are providing is eligible for a Resubmission, please contact the pCODR program.

Examples of issues to consider include: what are the impacts of the condition on patients' daily living? Are the needs of patients being met by existing therapies? Are there unmet needs? Will the agents included in this recommendation affect the lives of patients? Do they have any disadvantages? Stakeholders may also consider other factors not listed here.

Page Number	Section Title	Paragraph, Line Number	Comments related to initial patient group input

1.3 Additional Comments About the Initial Recommendation Document

Please provide any additional comments:

Page Number	Section Title	Paragraph, Line Number	Additional Comments